Alebund Pharmaceuticals Nets HK$1.2 Billion in Hong Kong IPO

MT Newswires Live
06/29

Alebund Pharmaceuticals (Jiangsu) (HKG:9637) raised HK$1.18 billion in net proceeds from its initial public offering in Hong Kong, according to a Friday after-market filing on the Hong Kong Exchange.

The biopharmaceutical company priced its IPO at HK$22.60 per share, issuing roughly 56.8 million shares.

The Hong Kong public offering portion of the deal was 963.56 times subscribed, with a final allocation of 5.68 million shares.

The international offering was 19.77 times subscribed, with 51.08 million shares allocated.

Cornerstone investors were allotted 28.3 million shares, accounting for 49.78% of the IPO shares.

Alebund Pharma is set to debut on the Hong Kong bourse today, June 29.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10